PEAK6 Investments L.P. purchased a new position in shares of 1-800-PetMeds (NASDAQ:PETS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 9,653 shares of the company’s stock, valued at approximately $439,000.
Other hedge funds have also recently made changes to their positions in the company. LS Investment Advisors LLC raised its position in shares of 1-800-PetMeds by 283.5% during the 4th quarter. LS Investment Advisors LLC now owns 2,861 shares of the company’s stock valued at $130,000 after purchasing an additional 2,115 shares during the period. Sterling Investment Advisors Ltd. raised its position in shares of 1-800-PetMeds by 118.5% during the 4th quarter. Sterling Investment Advisors Ltd. now owns 2,950 shares of the company’s stock valued at $134,000 after purchasing an additional 1,600 shares during the period. Sei Investments Co. raised its position in shares of 1-800-PetMeds by 50,142.9% during the 3rd quarter. Sei Investments Co. now owns 3,517 shares of the company’s stock valued at $117,000 after purchasing an additional 3,510 shares during the period. CenterStar Asset Management LLC bought a new stake in shares of 1-800-PetMeds during the 4th quarter valued at $169,000. Finally, OppenheimerFunds Inc. bought a new stake in shares of 1-800-PetMeds during the 4th quarter valued at $202,000. Hedge funds and other institutional investors own 91.25% of the company’s stock.
In other news, CEO Menderes Akdag sold 30,000 shares of the business’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $51.00, for a total value of $1,530,000.00. Following the sale, the chief executive officer now directly owns 490,000 shares in the company, valued at approximately $24,990,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronald J. Korn sold 5,000 shares of 1-800-PetMeds stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $48.38, for a total transaction of $241,900.00. Following the transaction, the director now directly owns 68,833 shares of the company’s stock, valued at $3,330,140.54. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,000 shares of company stock worth $2,341,900. Insiders own 4.00% of the company’s stock.
NASDAQ PETS traded down $0.54 on Friday, reaching $41.19. The company had a trading volume of 381,629 shares, compared to its average volume of 447,692. The company has a market cap of $859.68, a P/E ratio of 35.21, a P/E/G ratio of 1.94 and a beta of 0.98. 1-800-PetMeds has a 12 month low of $20.96 and a 12 month high of $57.80.
1-800-PetMeds (NASDAQ:PETS) last announced its quarterly earnings results on Monday, January 22nd. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.11. 1-800-PetMeds had a net margin of 12.84% and a return on equity of 34.04%. The company had revenue of $60.10 million for the quarter, compared to the consensus estimate of $56.76 million. During the same period in the previous year, the firm posted $0.24 EPS. 1-800-PetMeds’s revenue for the quarter was up 13.6% compared to the same quarter last year. equities analysts anticipate that 1-800-PetMeds will post 1.77 earnings per share for the current fiscal year.
Several brokerages have recently commented on PETS. BidaskClub downgraded shares of 1-800-PetMeds from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 19th. Northcoast Research set a $58.00 price target on shares of 1-800-PetMeds and gave the company a “buy” rating in a report on Wednesday, January 3rd. Finally, ValuEngine downgraded shares of 1-800-PetMeds from a “buy” rating to a “hold” rating in a report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $42.80.
TRADEMARK VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/peak6-investments-l-p-takes-position-in-petmed-express-inc-pets.html.
1-800-PetMeds Company Profile
PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. It provides non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, as well as generic substitutes.
Receive News & Ratings for 1-800-PetMeds Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 1-800-PetMeds and related companies with MarketBeat.com's FREE daily email newsletter.